[MCW IRB-CML MOU] Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients who Relapsed After a Prior Attempt at TKI Discontinuation
The purpose of this study is to compare the good and bad effects of adding ruxolitinib to the standard chemotherapy vs. using the standard chemotherapy alone.
This study is also looking at the toxicities, progression free survival and overall survival rates in this patient population.
Chronic Myeloid Leukemia (CP-CML)
1. Age ≥18
2. Willing and able to give informed consent
3. Diagnosed with CML in chronic phase
4. Previous treatment with at least one tyrosine kinase inhibitor (TKI) such as imatinib, nilotinib, dasatinib, radotinib or ponatinib
Other eligibility will apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Total duration of the trial will be approximately four years (one year on combination treatment phase + three years in the TFR phase).
Clinical Trials Information Line
This study is funded by the Incyte Corporation and lead by Sponsor-Investigator, Kendra Sweet at the H. Lee Moffitt Cancer Center.